journal
MENU ▼
Read by QxMD icon Read
search

Journal of Virus Eradication

journal
https://www.readbyqxmd.com/read/29682309/australasian-society-for-hiv-viral-hepatitis-and-sexual-health-medicine-hiv-pre-exposure-prophylaxis-clinical-guidelines-update-april-2018
#1
EDITORIAL
Edwina Wright, Andrew Grulich, Katy Roy, Mark Boyd, Vincent Cornelisse, Darren Russell, Darryl O'Donnell, Bill Whittaker, Levinia Crooks, Iryna Zablotska
Daily use of coformulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines. These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine's (ASHM) PrEP Guidelines are an updated adaptation of the 2014 US Centers for Disease Control's PrEP guidelines and are designed to: •Support the prescription of PrEP using forms of coformulated tenofovir and emtricitabine that have been registered in Australia by the Therapeutic Goods Administration and other bioequivalent generic drugs that are available in Australia through self-importation, private prescription or Australian PrEP clinical trials•Assist clinicians in the evaluation of patients who are seeking PrEP•Assist clinicians in commencing and monitoring patients on PrEP including PrEP dosing schedules, management of side-effects and toxicity, use of PrEP in pregnancy and in chronic hepatitis B infection and how to cease PrEP Daily PrEP with co-formulated tenofovir and emtricitabine, used continuously or for shorter periods of time, is recommended in these guidelines as a key HIV-prevention option for men who have sex with men (MSM), transgender men and women, heterosexual men and women, and people who inject drugs (PWID) at substantial risk of HIV acquisition...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682308/highlights-from-the-8-th-international-workshop-on-hiv-persistence-during-therapy-12-15-december-2017-miami-fl-usa
#2
EDITORIAL
Christina K Psomas, Alain Lafeuillade, David Margolis, Karl Salzwedel, Mario Stevenson, Nicolas Chomont, Guido Poli, Jean-Pierre Routy
Over 4 days, more than 500 scientists involved in HIV persistence research shared their new unpublished data and designed future perspectives towards ART-free HIV remission. This 8th International Workshop on HIV Persistence followed the format of past conferences but further focused on encouraging participation of young investigators, especially through submission of oral and poster presentations. The topic of the workshop was HIV persistence. Consequently, issues of HIV reservoirs and HIV cure were also addressed...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682307/bioequivalent-pharmacokinetics-for-generic-and-originator-hepatitis-c-direct-acting-antivirals
#3
EDITORIAL
Andrew Hill, Loai Tahat, Mohammed Khalil Mohammed, Rabab Fayez Tayyem, Giten Khwairakpam, Sanjay Nath, James Freeman, Ismahane Benbitour, Sherine Helmy
Mass production of low-cost, generic direct-acting antivirals (DAAs) will be required to achieve targets of eliminating hepatitis C (HCV) by 2030. The pharmaceutical companies Gilead and Bristol-Myers Squibb have granted voluntary licences (VLs) to generic companies to mass produce the DAAs sofosbuvir and daclatasvir at low cost. However, generic manufacturers need to demonstrate bioequivalent pharmacokinetics for their DAAs, compared to the originator versions, to fulfil World Health Organization standards for prequalification...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682306/anti-m%C3%A3-llerian-hormone-levels-are-reduced-in-women-living-with-human-immunodeficiency-virus-compared-to-control-women-a-case-control-study-from-copenhagen-denmark
#4
EDITORIAL
Maria Wessman, Anne-Sofie Korsholm, Janne Gasseholm Bentzen, Anders Nyboe Andersen, Magnus Glindvad Ahlström, Terese Lea Katzenstein, Nina Weis
Objectives: Anti-müllerian hormone (AMH) is a marker of ovarian reserve. The purpose of this study was to compare AMH in women living with HIV with an age-matched control group of HIV-uninfected women, and to identify possible variables associated with decreasing AMH levels in women living with HIV. Methods: AMH was measured in frozen EDTA samples from 84 white women living with HIV, aged 20 -40 years, with fully suppressed HIV RNA viral loads for at least 6 months and no hepatitis B or C virus co-infection...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682305/outpatient-directly-observed-therapy-for-hepatitis-c-among-people-who-use-drugs-a-systematic-review-and-meta-analysis
#5
EDITORIAL
Cara L McDermott, Catherine M Lockhart, Beth Devine
Objective:  We conducted a meta-analysis of randomised studies that assessed the effectiveness of directly observed hepatitis C medication therapy delivered in outpatient clinics compared to treatment as usual. Methods:  We completed a systematic literature review up to the end of August 2017, including online databases, study abstracts and references of pertinent articles. We assessed the results of randomised studies using the Cochrane Collaboration risk of bias assessment tool, and observational studies using the ROBINS-I tool...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682304/implementation-of-hepatitis-c-cure-in-australia-one-year-on
#6
EDITORIAL
Jacqueline A Richmond, Jack Wallace
Objectives: Direct-acting antivirals (DAAs) for the treatment of hepatitis C (HCV) became universally available in Australia in March 2016, with an aim to achieve HCV elimination. Fourteen per cent of Australians with HCV have initiated treatment. The objective of this study was to explore and identify challenges and enablers that have emerged during this initial phase of HCV cure implementation. Methods: Key stakeholders (KS) in primary care, non-government and government sectors were recruited to participate in a telephone-based semi-structured interview to describe challenges and enablers facing individuals with HCV and the healthcare system in implementing HCV cure...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682303/heterogeneity-in-hepatitis-c-treatment-prescribing-and-uptake-in-australia-a-geospatial-analysis-of-a-year-of-unrestricted-treatment-access
#7
EDITORIAL
Nick Scott, Samuel W Hainsworth, Rachel Sacks-Davis, Alisa Pedrana, Joseph Doyle, Amanda Wade, Margaret Hellard
Background and aim: Direct-acting antiviral (DAA) treatments became available for all people living with hepatitis C virus (HCV) in Australia in March 2016. We assess variations in treatment rates and prescribing patterns across Australia's 338 Statistical Area 3 (SA3) geographical units. Methods: Geocoded DAA treatment initiation data were analysed for the period 1 March 2016 to 30 June 2017. Regression models tested associations between the population demographics and healthcare service coverage of geographical areas and (a) their treatment rates; and (b) the proportion of prescriptions written by specialists compared to non-specialists...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682302/impact-of-an-educational-video-as-a-consent-tool-on-knowledge-about-cure-research-among-patients-and-caregivers-at-hiv-clinics-in-south-africa
#8
EDITORIAL
Melany Hendricks, Gonasagrie Nair, Ciara Staunton, Michael Pather, Nigel Garrett, Dianno Baadjies, Martin Kidd, Keymanthri Moodley
Background: Despite increasing access to antiretroviral therapy in low- and middle-income countries, only 54% of eligible individuals were receiving treatment in Africa by 2015. Recent developments in HIV cure research have been encouraging. However, the complex science and procedures of cure research render the informed consent process challenging. Objective: This study evaluates the impact of a video tool on educating participants about HIV cure. Methods: A questionnaire assessing the content of the video was administered to adults recruited from two clinics in South Africa...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682301/ethical-challenges-in-developing-an-educational-video-to-empower-potential-participants-during-consent-processes-in-hiv-cure-research-in-south-africa
#9
EDITORIAL
Ciara Staunton, Malcolm de Roubaix, Dianno Baatjies, Gill Black, Melany Hendricks, Theresa Rossouw, Keymanthri Moodley
Obtaining consent for HIV research is complex, particularly in low- and middle-income countries. Low levels of education, complexity of science and research processes, confusion about basic elements of research, and socio-economic conditions that make access to medical care difficult have collectively led to concerns about the adequacy of the consent process. Given the exponential growth of HIV prevention and treatment research in South Africa, HIV researchers are increasingly facing challenges obtaining authentic informed consent from potential participants...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682300/latent-hiv-dynamics-and-implications-for-sustained-viral-suppression-in-the-absence-of-antiretroviral-therapy
#10
EDITORIAL
John M Murray
Objectives: The interaction between HIV and the immune system gives rise to a complex dynamical system. We therefore investigate whether delayed viral rebound after antiretroviral therapy (ART) interruption (ATI) may be due to an individual's viral-immune state being in a region of relative stability, and if so, how this can be extended. Methods: Using a mathematical model duplicating plasma viral levels, HIV DNA and immune homeostatic dynamics for individuals on ART commenced at either primary (PHI) or chronic (CHI) HIV infection, we investigate whether latent reservoir reductions and perturbations in other infected and uninfected memory CD4+ T cell subsets can delay viral rebound...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682299/the-impact-of-hiv-prevalence-conflict-corruption-and-gdp-capita-on-treatment-cascades-data-from-137-countries
#11
EDITORIAL
Jacob Levi, Anton Pozniak, Katherine Heath, Andrew Hill
Objective: In 2014, UNAIDS and partners set the 90-90-90 targets for the HIV treatment cascade. Multiple social, political and structural factors might influence progress towards these targets. We assessed how close countries and regions are to reaching these targets, and compared cascade outcomes with HIV prevalence, gross domestic product (GDP)/capita, conflict and corruption. Methods: Country-level HIV cascade data on diagnosis, ART coverage and viral suppression, from 2010 to 2016 were extracted from national reports, published papers and the www...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682298/tenofovir-alafenamide-versus-tenofovir-disoproxil-fumarate-is-there-a-true-difference-in-efficacy-and-safety
#12
EDITORIAL
Andrew Hill, Sophie L Hughes, Dzintars Gotham, Anton L Pozniak
Background: Higher plasma tenofovir concentrations are associated with higher risks of renal and bone adverse events. The pharmacokinetic boosters ritonavir (RTV) and cobicistat (COBI) significantly increase plasma area under the curve (AUC) concentrations of tenofovir disoproxil fumarate (TDF), by 25-37%. When combined with RTV or COBI, the dose of tenofovir alafenamide (TAF) is lowered from 25 mg to 10 mg daily, but the TDF dose is maintained at 300 mg daily. Objective: To assess the differences in safety and efficacy between tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) in regimens with and without the pharmacokinetic boosters RTV and COBI...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682297/safety-and-pharmacokinetics-of-dolutegravir-in-hiv-positive-pregnant-women-a-systematic-review
#13
EDITORIAL
Andrew Hill, Polly Clayden, Claire Thorne, Rachel Christie, Rebecca Zash
Background: The integrase strand transfer inhibitor dolutegravir (DTG) is being introduced into low- and middle-income countries (LMICs) as an alternative to first-line treatment with non-nucleoside reverse transcriptase inhibitors. However, DTG is not yet widely recommended for use in pregnant women. The aim of this systematic review was to analyse all available data on birth outcomes and congenital anomalies in the infants of pregnant women treated with DTG. Methods: A PubMed and Embase search was conducted using the terms "dolutegravir" or "DTG" and "pregnancy" or "pregnant" from the earliest available date on the database to 26 July 2017...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29682296/intensification-of-antiretroviral-treatment-with-raltegravir-for-pregnant-women-living-with-hiv-at-high-risk-of-vertical-transmission
#14
EDITORIAL
Thanyawee Puthanakit, Nattawan Thepnarong, Surasith Chaithongwongwatthana, Suvaporn Anugulruengkitt, Orawan Anunsittichai, Tuangtip Theerawit, Sasiwimol Ubolyam, Chitsanu Pancharoen, Praphan Phanuphak
Objectives:  The rate of vertical HIV transmission for women at high risk of HIV transmission stands at approximately 7.6%. In the present study we describe infant infection rates in women who had received raltegravir (RAL) intensification during pregnancy to a standard three-drug antiretroviral (ART) regimen in Thailand. Methods:  This prospective cohort study enrolled HIV-1-positive pregnant women at high risk of vertical transmission, as defined by (1) ART initiation at a gestational age (GA) ≥32 weeks or (2) HIV-1 RNA >1000 copies/mL at GA of 32-38 weeks while on ART...
April 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29568557/art-and-viral-hepatitis-elimination-programmes
#15
EDITORIAL
Maryam Nima, Hamidreza Karimi-Sari, Seyed Moayed Alavian
The elimination viral hepatitis requires increased awareness of the viruses that cause it by the general population. To this end, the Iran Hepatitis Network held the First Drawing and Illustration Contest with the theme of eliminating hepatitis. We suggest that artwork provided by the general public could have a role in campaigns promoting hepatitis elimination.
January 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29568556/highlights-from-the-hiv-cure-and-reservoir-symposium-11-12-september-2017-ghent-belgium
#16
EDITORIAL
Sam Kint, Clarissa Van Hecke, Basiel Cole, Linos Vandekerckhove, Magdalena Sips
For the second time, the HIV Cure Research Center (HCRC) at Ghent University organised the HIV Cure and Reservoir Symposium, in Ghent, Belgium, where in this two-day conference, virologists, molecular biologists, immunologists and clinicians presented the most recent achievements in the field of HIV cure, including data on therapeutic vaccines, HIV remission strategies such as 'shock and kill' or 'block and lock', benefits of early ART and potential of haematopoietic stem cell transplant in achieving cure. Furthermore, methods to characterise and quantify the HIV reservoir were discussed along with HIV reservoir characterisation in different body parts, including the central nervous system...
January 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29568555/report-from-the-first-epiical-early-treated-perinatally-hiv-infected-individuals-improving-children-s-actual-life-with-novel-immunotherapeutic-strategies-general-assembly-meeting-9-11-november-2017-rome-italy
#17
EDITORIAL
P Zangari, P Palma, N Cotugno, P Rojo, A Tagarro, I Pepponi, A De Rossi, L Kuhn, S Pahwa, M Cameron, E Nastouli, S Watters, A G Marceline, L E McCoy, D Persaud, A Violari, M Chan, A G Babiker, C Foster, J Ananworanich, C Giaquinto, P Rossi
No abstract text is available yet for this article.
January 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29568554/highlights-from-the-htlv-1-symposium-at-the-2017-australasian-hiv-and-aids-conference-held-jointly-with-the-2017-australasian-sexual-health-conference-november-2017-canberra-australia
#18
EDITORIAL
Lloyd Einsiedel, Damian Purcell, Shane Schinke, Katelin Haynes, Graham P Taylor, Fabiola Martin
We are pleased to report on the inaugural HTLV-1 symposium at the 2017 Australasian HIV and AIDS Conference joint with 2017 Australasian Sexual Health Conference in Canberra, Australia. Our understanding of HTLV-1 epidemiology, pathogenesis, laboratory diagnostics and treatment options for HTLV-1 diseases has advanced tremendously over the last 40 years. However, the awareness of healthcare providers and the general population about HTLV-1, and the effective promotion and implementation of HTLV-1 transmission-prevention strategies, lag behind current knowledge...
January 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29568553/hiv-associated-cognitive-performance-and-psychomotor-impairment-in-a-thai-cohort-on-long-term-cart
#19
EDITORIAL
Tanya C Do, Stephen J Kerr, Anchalee Avihingsanon, Saowaluk Suksawek, Supalak Klungkang, Taweesak Channgam, Christoph C Odermatt, Wirach Maek-A-Nantawat, Kiat Ruxtungtham, Jintanat Ananworanich, Victor Valcour, Peter Reiss, Ferdinand W Wit
Objectives: To assess cognitive performance and psychomotor impairment in an HIV-positive cohort, well-suppressed on combination antiretroviral therapy (cART), in an Asian resource-limited setting. Methods: Cross-sectional sociodemographic and cognitive data were collected in 329 HIV-positive and 510 HIV-negative participants. Cognitive performance was assessed using the International HIV Dementia Scale (IHDS), Montreal Cognitive Assessment (MoCA), WAIS-III Digit Symbol, Trail Making A, and Grooved Pegboard (both hands)...
January 1, 2018: Journal of Virus Eradication
https://www.readbyqxmd.com/read/29568552/prevalence-and-factors-associated-with-renal-dysfunction-in-patients-on-tenofovir-disoproxil-fumarate-based-antiretroviral-regimens-for-hiv-infection-in-southern-india
#20
EDITORIAL
Nagalingeswaran Kumarasamy, Sruthi Sundaram, Selvamuthu Poongulali, Chandrasekaran Ezhilarasi, Ambrose Pradeep, Devaraj Chitra
Objectives: Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor commonly used in the treatment of HIV infection. This retrospective study aims to establish the prevalence of abnormal renal function among patients with HIV receiving TDF, and to investigate the risks for TDF-related renal dysfunction in this population. Methods: Patients at the YRGCARE Medical Centre, Voluntary Health Services, receiving TDF-containing antiretroviral (ART) regimens between January 2002 and March 2017, were assessed for renal dysfunction using creatinine level and eGFR (DAIDS/NIH) during continuum of care...
January 1, 2018: Journal of Virus Eradication
journal
journal
50095
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"